CHRS(Coherus Oncology, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $326.55M | $211.04M | $257.24M | $26.39M | $42.17M |
| 毛利润 | $268.96M | $140.96M | $98.25M | $17.66M | $28.36M |
| 营业利润 | −$263.86M | −$256.88M | −$203.20M | −$199.65M | −$181.13M |
| 净利润 | −$287.10M | −$291.75M | −$237.89M | $28.51M | $168.02M |
| 经营现金流 | −$37.43M | −$241.12M | −$174.88M | −$20.44M | −$138.51M |
| 自由现金流 | −$38.72M | −$243.16M | −$175.17M | — | — |
| 摊薄每股收益 | $-3.81 | $-3.76 | $-2.53 | $0.25 | $1.43 |